Testing a noninvasive device for heart disease risk
Part of Heart & circulation clinical trials.
This trial uses a noninvasive device to examine small blood vessels in people at high risk for heart disease. It may help doctors better understand who needs preventive care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the SCAPIS 1 study about 10 years ago.
- You have been invited to join the SCAPIS 2 main study.
- You have signed the consent form for the SCAPIS 2 main study.
- You do not have scarring, tattoos, or amputations that would prevent using the device on your skin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study invites people who already took part in the first SCAPIS study to have follow-up heart and lung imaging. It helps researchers learn how these organs change over time.
This trial looks at an individualized prevention approach for people who are at higher risk of heart and blood vessel problems. It aims to help lower future cardiovascular risk before heart disease develops.
This study looks for new body markers (including possible genetic traits) to better predict who is likely to have future cardiovascular events. Your results could help doctors estimate risk and choose prevention strategies more accurately.
This trial looks at how learning about your genetic risk for heart disease might help prevent it. You will get a personalized report and guidance.
This trial tests a new device that measures heart function without needing an invasive catheter. It aims to see if the device works as well as the standard right heart catheterization procedure.
This trial tests a wearable chest sensor (called HEMOTAG) to monitor heart events in people with long-standing Type 2 diabetes who also have heart disease or specific diabetes-related complications. The sensor is worn at home for short periods to catch early signs of heart trouble, aiming to improve personalized care.
Hear when a new Cardiovascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.